Brain Tumors

Stereotactic Radiosurgery: Gamma Knife

The 30- and 180-day survival rates (for the first 6 months of 2018) remained robust for Gamma Knife radiosurgery treatment, independent of tumor type.

Gamma Knife Radiosurgery: Survival by Tumor Type – Meningioma

The 30- and 180-day survival rates (for the first 6 months of 2018) remained robust for Gamma Knife radiosurgery treatment for tumor, independent of tumor type.

Gamma Knife Radiosurgery: Survival by Tumor Type – Schwannoma

The 30- and 180-day survival rates (for the first 6 months of 2018) remained robust for Gamma Knife radiosurgery treatment for tumor, independent of tumor type.

Gamma Knife Radiosurgery: Survival by Tumor Type – Pituitary

The 30- and 180-day survival rates (for the first 6 months of 2018) remained robust for Gamma Knife radiosurgery treatment for tumor, independent of tumor type.

Gamma Knife Radiosurgery: Survival by Tumor Type – Metastasis

The 30- and 180-day survival rates (for the first 6 months of 2018) remained robust for Gamma Knife radiosurgery treatment for tumor, independent of tumor type.

Gamma Knife Radiosurgery: Karnofsky Performance Scale (N = 253)

2018

Functional status is measured by the Karnofsky Performance Scale, a widely used 11-point scale correlating to percentage values from 100% (no evidence of disease, no symptoms) to 0% (death). In 91% of patients, performance status remained stable or improved after stereotactic radiosurgery. Change in status was defined as a change of ≥ 20 points.

Survival: Gamma Knife Stereotactic Radiosurgery

The 30- and 180-day survival rates for Gamma Knife® radiosurgery were 99% and 97%, respectively (for the first 6 months of 2018).